SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc. ("Synergy" or the "Company") (SGYP) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of New York, and Docketed under 18-cv-00873, is on behalf of a class consisting of investors who purchased or otherwise acquired Synergy securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Synergy securities between September 5, 2017 and November 14, 2017, both dates inclusive, you have until April 10, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here to join this class action]
Synergy is a biopharmaceutical company focused on development and commercialization of therapies to treat Gastro-Intestinal disorders and diseases. Throughout the Class Period, Synergy had only one FDA-approved commercial product, TRULANCE™ (plecanatide) ("Trulance"), a drug for the once-daily treatment of chronic idiopathic constipation ("CIC"). Trulance was approved by the FDA on January 19, 2017 and became available for purchase at the end of the first quarter of 2017. on September 5, 2017, the beginning of the Class Period, Synergy announced that it closed on a $300 million senior secured loan from CRG Partners III L.P. ("CRG" and the "CRG Loan"), providing an immediate cash infusion of $100 million with a second $100 million tranche of CRG Loan financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following 13 months. The Company's Executive Vice President Guy Gemignani extolled the newly-secured loan as "non-dilutive" to the equity interests of the Company's shareholders while providing a material boost to Synergy's "cash position."
As a result of these and further assurances that Synergy had: (i) arranged ample debt financing to keep its operations running through 2019; (ii) maintained a large capital cushion to achieve its business objectives; and (iii) had a manageable cash burn rate, the investing public was led to believe that Synergy could and would successfully develop and profit from Trulance without needing to raise additional capital through additional equity offerings and without diluting stockholders' outstanding equity interests.